Department of Pediatrics Archive — Page 53 of 57
-
October 28, 2013
Tool predicts risk for developmental delays in early childhood
A non-invasive measure of electrical brain activity in preterm infants predicts cognitive and communication functioning during early childhood, according to a new Vanderbilt University study. -
October 17, 2013
VUMC joins national stroke prevention research network
Vanderbilt University Medical Center has joined a national network funded by the National Institutes of Health to streamline multi-site clinical trials focused on key interventions in stroke prevention, treatment and recovery. -
October 17, 2013
Fellow tracks post-vaccination bacterial trends
Pediatric Infectious Diseases fellow Annabelle de St. Maurice, M.D., has been awarded a grant to determine the relationship between pneumococcal vaccination and the emergence of certain strains of pneumococcal bacteria not covered by vaccines. -
September 26, 2013
Vaccine Research Program lands major NIH renewal
The Vanderbilt Vaccine Research Program has received a major contract from the National Institutes of Health to continue its work as one of the nation’s Vaccine and Treatment Evaluation Units. -
September 19, 2013
VU testing vaccine against new flu threat
Vanderbilt’s Vaccine and Treatment Evaluation Unit (VTEU) is one of nine U.S. sites funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to test the effectiveness of a vaccine to protect against the H7N9 bird flu that emerged in China this spring. -
September 19, 2013
Hyundai award helps drive hope for cancer research
Emmanuel Volanakis, M.D., assistant professor of Pediatrics and Hematology/Oncology, was awarded a $250,000 Hyundai Hope On Wheels grant last week for his ongoing research into T-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer. -
September 12, 2013
VU tracking drug’s ability to prevent type 1 diabetes
Vanderbilt’s Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.